🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 9642859

    Use of capsazepine and analogs thereof to treat cancer

    The Board of Regents of the University of Texas System · Granted Tue May 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9642805

    Aptamer-loaded, biocompatible nanoconstructs for nuclear-targeted cancer therapy

    Northwestern University · Granted Tue May 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9642843

    Pharmaceutical compounds and use of same in cancer and tauopathies

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue May 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9636329

    Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors

    Northwestern University · Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9636406

    Method of treating cancer

    Intensity Therapeutics, Inc. · Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9632074

    Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition

    The Regents of the University of California · Granted Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9629385

    Dietary composition containing cistanche deserticola polysaccharide with inhibitory effects on colon cancer

    INFINITUS (CHINA) COMPANY LTD. · Granted Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9624211

    Anti-cancer compounds

    The Board of Regents of the University of Texas System · Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9623124

    Multimodal diagnostic technology for early stage cancer lesions

    Northwestern University · Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9624306

    Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9624255

    Carbohydrate-mediated tumor targeting

    THE ARIZONA BOARD OF REGENTS · Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9618513

    Compositions and methods for detecting and treating colorectal cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9616047

    Inhibitors of beta-catenin in treatment of colorectal cancer

    Regents of the University of Minnesota · Granted Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9611330

    Compositions and methods for cancer and cancer stem cell detection and elimination

    The Regents of the University of California · Granted Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9611266

    Compounds and anti-tumor NQO1 substrates

    The Board of Regents of the University of Texas System · Granted Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9605077

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9604973

    Anti-cancer polyketide compounds

    The Regents of the University of California · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9606124

    Methods of detecting and treating stem-cell containing solid tumors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9603820

    Ornithine aminotransferase inhibition with GABA analogues for treatment of hepatocellular carcinoma

    Northwestern University · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9598697

    Recombinant bacterium to decrease tumor growth

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Mar 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9592304

    Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9592290

    Monoclonal antibody therapy for pancreas cancer

    PRECISION BIOLOGICS, INC. · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9593162

    Internalizing human monoclonal antibodies targeting prostate cancer cells in situ

    The Regents of the University of California · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9585928

    Agave syrup extract having anticancer activity

    INSTITUTO TECNOLÓGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY · Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9580438

    Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders

    4SC DISCOVERY GMBH · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9579406

    Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof

    CELLECTAR BIOSCIENCES, INC. · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9572828

    Treatment for melanoma

    The Board of Regents of the University of Texas System · Granted Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9567402

    Internalizing human monoclonal antibodies targeting prostate and other cancer cells

    The Regents of the University of California · Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9566294

    Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis

    Northwest Biotherapeutics, Inc. · Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9566348

    Methods and compositions for the treatment of cancer and infectious disease using alpha(2) macroglobulin-antigenic molecule complexes

    University of Connecticut Health Center · Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9567643

    Compositions and methods for treating cancers

    APTOSE BIOSCIENCES INC. · Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9568476

    Diagnosis and treatment of breast cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9562070

    Induction of tumor immunity by variants of folate binding protein

    The Board of Regents of the University of Texas System · Granted Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9561245

    Combination treatments for melanoma

    The Board of Regents of the University of Texas System · Granted Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9562237

    Reduction of TGF beta signaling in myeloid cells in the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9556113

    Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment

    SOUTH DAKOTA BOARD OF REGENTS · Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9551713

    Use of a panel of urinary cytokines to predict response to BCG therapy for bladder cancer

    The Board of Regents of the University of Texas System · Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9546368

    Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression

    Ionis Pharmaceuticals, Inc. · Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9545443

    Methods and agents for the diagnosis and treatment of hepatocellular carcinoma

    China Synthetic Rubber Corporation · Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9540641

    Cancer treatment

    Ionis Pharmaceuticals, Inc. · Granted Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9539340

    Bladder cancer specific ligand peptides

    The Regents of the University of California · Granted Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9539231

    Method for treating triple-negative breast cancer using AMPI-109

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9534033

    Targeted interferons demonstrating potent apoptotic and anti-tumor activities

    The Regents of the University of California · Granted Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9527919

    High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection

    The Regents of the University of California · Granted Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9522955

    Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9522910

    Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon

    OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU “FUSION PHARMA” · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9522185

    Human antibodies to GFR α3 and methods of treating pain associated with osteoarthritis or bone cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9523691

    Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis

    INSTITUT DE CANCEROLOGIE DE L'OUEST · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.